AAD2026:Late-BreakingNemolizumabDataDemonstrateClinicallyMeaningfulBenefitsforChildrenAged2to11WithModerate-to-SevereAtopicDermatitis
===2026/3/30 11:39:27===
world, cross-sectional survey.Pediatr Dermatology. 2025;42:523-531. doi:10.1111/pde.15940
Vittrup I, et al. The association between atopic dermatitis, cognitive function and school performance in children and young adults.Br J Dermatol. 2023;188(3):341-349. doi: 10.1093/bjd/ljac058
Mostafa N and Smith S D. Improving psychological health outcomes in children with atopic dermatitis.Clin Cosmet Investig Dermatol.2023;16:2821-2827. doi: 10.2147/CCID.S393254
Kelly K A, et al. Skin disease in children: Effects on quality of life, stigmatization, bullying, and suicide risk in pediatric acne, atopic dermatitis, and psoriasis patients.Children (Basel).2021;8(11):1057. doi:10.3390/children8111057
Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.J Allergy Clin Immunol. 2020;145(1): 173-182. doi: 10.1016/j.jaci.2019.08.013
Bewley A, et al. Prurigo nodula
=*=*=*=*=*=
当前为第8/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页